Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

Many roads lead to Rome: The FGF4–AMP‐activated protein kinase–Caspase 6 signal axis in NAFLD and NASH

(2022) Alena Laschtowitz et al.   HEPATOLOGY

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

(2022) Tobias Puengel et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

(2021) Manal F. Abdelmalek et al.   Contemporary Clinical Trials

Mechanisms and disease consequences of nonalcoholic fatty liver disease

(2021) Rohit Loomba et al.   CELL

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

(2021) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?

(2020) Michael Ritchie et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges

(2020) Sander Lefere et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

(2020) Vlad Ratziu et al.   HEPATOLOGY

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

(2020) Tracey G Simon et al.   GUT

Immunological mechanisms and therapeutic targets of fatty liver diseases

(2020) Hua Wang et al.   Cellular & Molecular Immunology

Sex Differences in NAFLD : State of the Art and Identification of Research Gaps

(2019) Amedeo Lonardo et al.   HEPATOLOGY

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

(2019) Oliver Krenkel et al.   GUT

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

(2019) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

(2019) Quentin M. Anstee et al.   Contemporary Clinical Trials

New drugs for NAFLD: lessons from basic models to the clinic

(2019) Katharina C. Reimer et al.   Hepatology International

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Fibroblast growth factor 21 in non-alcoholic fatty liver disease

(2019) Bradley Tucker et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

(2018) Oliver Krenkel et al.   HEPATOLOGY

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

(2018) Scott L. Friedman et al.   HEPATOLOGY

Effects of a PEGylated fibroblast growth factor 21 variant on steatosis, inflammation, and fibrosis in a mouse model of nonalcoholic steatohepatitis

(2018) B. Zinker et al.   JOURNAL OF HEPATOLOGY

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

(2018) Chris Estes et al.   JOURNAL OF HEPATOLOGY

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

(2018) Zobair Younossi et al.   HEPATOLOGY

An update on the recent advances in antifibrotic therapy

(2018) Frank Tacke et al.   Expert Review of Gastroenterology & Hepatology

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease

(2017) S Lefere et al.   INTERNATIONAL JOURNAL OF OBESITY

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

(2017) Tobias Puengel et al.   PLoS One

Liver Fibrosis: From Pathogenesis to Novel Therapies

(2016) Ralf Weiskirchen et al.   DIGESTIVE DISEASES

Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease

(2016) Matthias Bartneck et al.   HEPATOLOGY

Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury

(2016) Jana C. Mossanen et al.   HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

(2016) Eric Lefebvre et al.   PLoS One

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Dual effects of fibroblast growth factor 21 on hepatic energy metabolism

(2015) Ricardo J Samms et al.   JOURNAL OF ENDOCRINOLOGY

Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding

(2014) K. R. Markan et al.   DIABETES

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+macrophage infiltration in mice

(2014) Christer Baeck et al.   HEPATOLOGY

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

(2014) Pierre Bedossa et al.   HEPATOLOGY

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis

(2013) Masahiko Matsumoto et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research

(2012) David Kleiner et al.   SEMINARS IN LIVER DISEASE

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

Fibroblast Growth Factor 21 Corrects Obesity in Mice

(2008) Tamer Coskun et al.   ENDOCRINOLOGY